Skip to main content
icon for Will Johnson & Johnson (JNJ) beat quarterly earnings?
Finance·JNJ

Will Johnson & Johnson (JNJ) beat quarterly earnings?

icon for Will Johnson & Johnson (JNJ) beat quarterly earnings?
Finance·JNJ

Will Johnson & Johnson (JNJ) beat quarterly earnings?

Jul 15

Jul 15

81% szansa
Polymarket
NOWE
81% szansa
Polymarket
NOWE
As of market creation, Johnson & Johnson is estimated to release earnings on July 15, 2026. The Street consensus estimate for Johnson & Johnson’s non-GAAP EPS for the relevant quarter is $2.85 as of market creation. This market will resolve to "Yes" if Johnson & Johnson reports non-GAAP EPS greater than $2.85 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Johnson & Johnson releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS. Johnson & Johnson’s Q2 2026 earnings release, scheduled for July 15, anchors current trader sentiment, with the consensus EPS estimate holding steady at $2.85 versus $2.77 a year earlier. The modest Q1 beat ($2.70 actual versus $2.68–$2.66 expected) and subsequent upward revision to full-year adjusted EPS guidance of $11.55 reflect resilient demand for Darzalex and Tremfya that has only partially offset the sharp Stelara revenue decline from biosimilar competition. With estimates largely unchanged in recent weeks and the bar elevated after the April raise, market-implied odds tilt slightly toward a miss or narrow outcome, underscoring the uncertainty around whether new-product momentum will again exceed the consensus threshold amid ongoing portfolio transitions.

As of market creation, Johnson & Johnson is estimated to release earnings on July 15, 2026. The Street consensus estimate for Johnson & Johnson’s non-GAAP EPS for the relevant quarter is $2.85 as of market creation. This market will resolve to "Yes" if Johnson & Johnson reports non-GAAP EPS greater than $2.85 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents.

If Johnson & Johnson releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.)

If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”

Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Wolumen
$220
Data zakończenia
Jul 15, 2026
Rynek otwarty
Jul 2, 2026, 7:53 PM ET

Źródło rozstrzygnięcia

https://seekingalpha.com/

Resolver

0x65070BE91...
As of market creation, Johnson & Johnson is estimated to release earnings on July 15, 2026. The Street consensus estimate for Johnson & Johnson’s non-GAAP EPS for the relevant quarter is $2.85 as of market creation. This market will resolve to "Yes" if Johnson & Johnson reports non-GAAP EPS greater than $2.85 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Johnson & Johnson releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
As of market creation, Johnson & Johnson is estimated to release earnings on July 15, 2026. The Street consensus estimate for Johnson & Johnson’s non-GAAP EPS for the relevant quarter is $2.85 as of market creation. This market will resolve to "Yes" if Johnson & Johnson reports non-GAAP EPS greater than $2.85 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Johnson & Johnson releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS. Johnson & Johnson’s Q2 2026 earnings release, scheduled for July 15, anchors current trader sentiment, with the consensus EPS estimate holding steady at $2.85 versus $2.77 a year earlier. The modest Q1 beat ($2.70 actual versus $2.68–$2.66 expected) and subsequent upward revision to full-year adjusted EPS guidance of $11.55 reflect resilient demand for Darzalex and Tremfya that has only partially offset the sharp Stelara revenue decline from biosimilar competition. With estimates largely unchanged in recent weeks and the bar elevated after the April raise, market-implied odds tilt slightly toward a miss or narrow outcome, underscoring the uncertainty around whether new-product momentum will again exceed the consensus threshold amid ongoing portfolio transitions.

As of market creation, Johnson & Johnson is estimated to release earnings on July 15, 2026. The Street consensus estimate for Johnson & Johnson’s non-GAAP EPS for the relevant quarter is $2.85 as of market creation. This market will resolve to "Yes" if Johnson & Johnson reports non-GAAP EPS greater than $2.85 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents.

If Johnson & Johnson releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.)

If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”

Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Wolumen
$220
Data zakończenia
Jul 15, 2026
Rynek otwarty
Jul 2, 2026, 7:53 PM ET

Źródło rozstrzygnięcia

https://seekingalpha.com/

Resolver

0x65070BE91...
As of market creation, Johnson & Johnson is estimated to release earnings on July 15, 2026. The Street consensus estimate for Johnson & Johnson’s non-GAAP EPS for the relevant quarter is $2.85 as of market creation. This market will resolve to "Yes" if Johnson & Johnson reports non-GAAP EPS greater than $2.85 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Johnson & Johnson releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.

Uważaj na linki zewnętrzne.

Często zadawane pytania

"Will Johnson & Johnson (JNJ) beat quarterly earnings?" to rynek prognoz na Polymarket, gdzie traderzy kupują i sprzedają udziały "Tak" lub "Nie" w zależności od tego, czy wierzą, że to wydarzenie nastąpi. Obecne zbiorowe prawdopodobieństwo to 81% na "Yes". Na przykład, jeśli "Tak" kosztuje 81¢, rynek zbiorowo przypisuje 81% szansy na to, że to wydarzenie nastąpi. Te kursy zmieniają się ciągle, gdy traderzy reagują na nowe informacje i wydarzenia. Udziały w poprawnym wyniku można wymienić na $1 za sztukę po rozstrzygnięciu rynku.

"Will Johnson & Johnson (JNJ) beat quarterly earnings?" to nowo utworzony rynek na Polymarket, uruchomiony Jul 2, 2026. Jako wczesny rynek, to Twoja okazja, aby być jednym z pierwszych traderów, którzy ustalą kursy i określą początkowe sygnały cenowe rynku. Możesz też dodać tę stronę do zakładek, aby śledzić wolumen i aktywność handlową w miarę rozwoju rynku.

Aby handlować na "Will Johnson & Johnson (JNJ) beat quarterly earnings?", wybierz, czy uważasz, że odpowiedź to "Tak" czy "Nie". Każda strona ma bieżącą cenę odzwierciedlającą implikowane prawdopodobieństwo rynku. Wpisz kwotę i kliknij "Handluj". Jeśli kupisz udziały "Tak" i wynik okaże się "Tak", każdy udział wypłaci $1. Jeśli okaże się "Nie", Twoje udziały "Tak" wypłacą $0. Możesz też sprzedać swoje udziały w dowolnym momencie przed rozstrzygnięciem, jeśli chcesz zrealizować zysk lub ograniczyć stratę.

Obecne prawdopodobieństwo dla "Will Johnson & Johnson (JNJ) beat quarterly earnings?" to 81% na "Yes". Oznacza to, że społeczność Polymarket uważa, że istnieje 81% szansy na to, że to wydarzenie nastąpi. Te kursy aktualizują się w czasie rzeczywistym na podstawie rzeczywistych transakcji, dostarczając ciągle aktualizowany sygnał tego, czego rynek oczekuje.

Zasady rozstrzygania "Will Johnson & Johnson (JNJ) beat quarterly earnings?" określają dokładnie, co musi się wydarzyć, aby każdy wynik został ogłoszony zwycięzcą — w tym oficjalne źródła danych używane do ustalenia wyniku. Możesz przejrzeć pełne kryteria rozstrzygania w sekcji "Zasady" na tej stronie nad komentarzami. Zalecamy dokładne zapoznanie się z zasadami przed handlem, ponieważ określają one precyzyjne warunki, przypadki graniczne i źródła regulujące rozstrzyganie tego rynku.